Aquestive Therapeutics, Inc. (NASDAQ: AQST)

Aquestive Therapeutics, Inc. (AQST) operates in the pharmaceutical industry, focusing on the development and manufacture of innovative pharmaceutical products. The company's proprietary technology, PharmFilm, enables the creation of medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, and consistent therapeutic dosing.

Aquestive's primary business activities involve creating complex molecule-based product candidates for pharmaceutical companies, which then market and sell them globally. The company's commitment to innovation is reflected in its product pipeline, which includes AQST-109, a sublingual film formulation of epinephrine for the emergency treatment of allergic reactions, including anaphylaxis, and AQST-108, a buccally administered soluble film formulation of dipivefrin for the treatment of conditions other than anaphylaxis. Additionally, Libervant, a buccally administered soluble film formulation of diazepam, is in development for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity.

Aquestive's competitive advantages stem from its proprietary PharmFilm technology, which facilitates the delivery of complex molecules through alternative administrations, often improving upon invasive and inconvenient standard of care therapies. The company's commitment to research and development has led to an impressive portfolio of licensed commercial products, including Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, and Sympazan. These products are marketed and sold by the company's licensees, generating revenue for Aquestive through royalties and milestone payments.

The pharmaceutical industry is highly competitive, with Aquestive contending against established companies and emerging players. To maintain its competitive position, Aquestive seeks patent protection for its product candidates and related technology, relying on trademarks as well. Additionally, the company complies with extensive regulations set forth by the FDA and other regulatory authorities, ensuring adherence to clinical trials, manufacturing, labeling, and marketing guidelines.

Aquestive's product portfolio includes Suboxone, an oral film formulation of buprenorphine and naloxone for the treatment of opioid dependence, Exservan, an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS), and KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Furthermore, Zuplenz, an oral soluble film formulation of ondansetron, treats nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily product, is used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six years or older, while Sympazan, an oral soluble film formulation of clobazam, is employed for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged two years or older.